Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, October 28, 2026

Back to today

From X

@SouthernValue95

SouthernValue on X

Right now AI diffusion is happening faster in enterprise than in consumer. $MSFT is effectively the only pure play on enterprise AI diffusion. It’s salesforce, FDE and partner ecosystem, and the security, orchestration and governance capabilities of its platform uniquely unlock new AI TAM in traditional conservative enterprises. My prediction that M365 commercial would accelerate to >20% growth may come true next quarter, based on tonight’s guide. Sooner than I expected*. $MSFT will now have Azure and M365, which are 2/3 of revenue, growing >50% and >20%. And both stand a good chance of accelerating through the year: more copilot rollout, consumption pricing, and Autopilot for M365, and more capacity coming online and price increases for Azure. I still think $24-25 EPS is achievable in CY27 which would make $MSFT <22x fwd PE, even after a nice run. *helped by re-segmenting which added GitHub! But I think will be true this year regardless.
@SouthernValue95

SouthernValue on X

My prediction that M365 commercial would accelerate to >20% growth may come true next quarter, based on tonight’s guide. Sooner than I expected*. Right now AI diffusion is happening faster in enterprise than in consumer. $MSFT is effectively the only pure play on enterprise AI diffusion. It’s salesforce, FDE and partner ecosystem, and the security, orchestration and governance capabilities of its platform uniquely unlock new AI TAM in traditional conservative enterprises. $MSFT will now have Azure and M365, which are 2/3 of revenue, growing >50% and >20%. And both stand a good chance of accelerating through the year: more copilot rollout, consumption pricing, and Autopilot for M365, and more capacity coming online and price increases for Azure. I still think $24-25 EPS is achievable in CY27 which would make $MSFT <22x fwd PE, even after a nice run. *helped by re-segmenting which added GitHub! But I think will be true this year regardless.
@orrdavid

David Orr on X

Another thing: This post is *not* meant to call a short term top. I sometimes want to. Maybe even I have hinted that's what I think. But that's wrong. The best way to think is, "I don't know when the top will be, maybe $SOXX really does take another 100% leg up first, who knows, why not." But that next big move up or down seems like a pure guess to me. So at least for making a binary bet - a bet on $SOXX beta - it's a pure casino. There probably is some brilliant way to structure this trade, though. You're long compute and you're short the things that more intelligence kills - like really kills, not that benefits from AI letting them cut 90% of their staff. For my part, there are just way too many eyes on the trade for me to be all that interested, though. Because if too many smart people figure out how to solve that fundamentally guess what ... the long/short could easily blow up in a month, just before the collapse, since the market won't often give such large crowds a free lunch pair trade. I say screw all of that, better to just focus on real investments, in the real world, that likely benefit from AI or at least don't get hurt. That is not a gamble today, and lots of those stocks are just straight up cheap. The only downside is that the AI trade will probably keep the stocks trading weak ... but this side is NOT hard to do broad, uncrowded pair trades on, so who cares.

Investor Letters

All letters

Danaher’s robotics era

Danaher’s new CEO paired a Q3 beat and raised EPS outlook with a 2027 4%-5% organic-growth starting point, while pitching AI-enabled…

DHR $163B
Best Anchor Stocks 1 click
GPC · long

Genuine Parts CO

Genuine Parts trades at roughly 9x EBITDA as cyclical weakness and elevated NAPA investment temporarily depress earnings.

GPC $17B
Value Investors Club 2 clicks

Checking Out Music Royalties

Mills Music Trust's 8.5% yield faces declining distributions as songs enter the public domain, while Royalty Exchange lists more than 700…

MMTRS
Exploring with Alluvial Capital

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $1.9B
John Hempton's Newsletter 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 73 of 273

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

307 firms

Sectors

Ordered by how often our editor reaches for them.